Top

Published in:

01-05-2014 | Coronary Heart Disease (JA Farmer, Section Editor)

The Role of Nonpharmacologic Device Interventions in the Management of Drug-Resistant Hypertension

Authors: William H. Frishman, Daniel Glicklich

Published in: Current Atherosclerosis Reports | Issue 5/2014

Abstract

Resistant systemic hypertension in patients is defined as the inability to control blood pressure despite taking at least three antihypertensive drugs, one of which is a diuretic. Two nonpharmacologic approaches are being evaluated in resistant hypertensive patients. First, the Rheos® Baroreflex Hypertension Therapy system is an implantable device that activates the carotid baroreflex through electrical stimulation of the carotid sinus wall. Sustained and clinically lower blood pressure has been observed in patient clinical trials. The second approach is a catheter-based strategy which denervates the renal afferent and efferent autonomic nervous system. This strategy has also been shown to be effective in drug-resistant patients, and has also been shown to decrease renin production, preserve renal function, improve glucose tolerance, and reduce left ventricular hypertrophy. Both carotid sinus stimulation and renal denervation are now being evaluated in clinical trials for the long-term control of hypertension.

• Roger VL, Go AS, Lloyd Jones DM, et al. Heart disease and stroke statistics, 2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220. High BP remains a major cause of morbidity and mortality.PubMedCrossRef

Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–215.PubMedCrossRef

Egan BM, Zhao Y, Axon RN. U.S. trends in prevalence, awareness, treatment, and control of hypertension. JAMA. 2010;303:2043–50.PubMedCrossRef

Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.PubMedCrossRef

•• Daugherty SL, Powers D, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–42. Resistant hypertension with drug therapy is associated with increased risk of major adverse cardiovascular events.PubMedCentralPubMedCrossRef

Ng MM, Sica DA, Frishman WH. Rheos: an implantable carotid sinus stimulation device for the nonpharmacologic treatment of resistant hypertension. Cardiol Rev. 2011;19:52–7.PubMedCrossRef

Lohmeier TE, Irwin ED, Rossing MA, et al. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43:306–11.PubMedCrossRef

•• Krum H, Sobotka P, Mahfoud F, et al. Device-based antihypertensive therapy. Therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209–15.PubMedCrossRef

•• Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol. 2011;58:765–73. In this pivotal trial, long-term therapy with carotid sinus baroreflex activation therapy was found to be effective in treating patients with resistant hypertension.PubMedCrossRef

10.

Jordan J, Heusser K, Brinkmann J, Tank J. Electrical carotid sinus stimulation in treatment resistant arterial hypertension. Auton Neurosci. 2012;172:31–6.PubMedCrossRef

11.

Lovic D, Aj M, Lovic B, et al. The pathophysiological basis of carotid baroreceptor stimulation for the treatment of resistant hypertension. Curr Vasc Pharmacol. 2013. PMID: 23905596.

12.

Esler M, Krum H, Sobotka P, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1878–80.CrossRef

13.

Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932–4. PMID: 23905592.

14.

Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRef

15.

• Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.CrossRef

16.

Briasoulis A, Bakris G. The future of interventional management of hypertension: threats and opportunities. Curr Vasc Pharmacol. 2013.

17.

Chapleau MW. Arterial baroreflexes. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension primer. 4th ed. Dallas: American Heart Association; 2008. p. 120–3.

18.

Dunlap ME. Cardiopulmonary baroreflexes. In: Izzo Jr JR, Sica DA, Black HR, editors. Hypertension primer. 4th ed. Dallas: American Heart Association; 2008. p. 123–5.

19.

Zar T, Peixoto AJ. Paroxysmal hypertension due to baroreflex failure. Kidney Int. 2008;74:126–31.PubMedCrossRef

20.

Sica DA. Baroreflex activation in drug-resistant hypertension. US Cardiol. 2009;6(1):29–32.

21.

Lohmeier TE, Dwyer TM, Irwin ED, et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007;49:1307–14.PubMedCrossRef

22.

Lohmeier TE, Hildebrandt DA, Dwyer TM, et al. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension. 2007;49:373–9.PubMedCrossRef

23.

Scheffers I, Kroon AA, Tordoir J, et al. Rheos® Baroreflex Hypertension Therapy™ system to treat resistant hypertension. Expert Rev Med Devices. 2008;5:33–9.PubMedCrossRef

24.

Sica DA, Lohmeier TE. Baroreflex activation for the treatment of hypertension: principles and practice. Expert Rev Med Devices. 2006;3:595–601.PubMedCrossRef

25.

Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44(6):1213–8.PubMedCrossRef

26.

Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;5(56):1254–8.CrossRef

27.

Bakris G, Bisognano J, Nadim M, et al. Potential of implantable carotid sinus stimulator for drug-resistant hypertension. Paper presented at: 23rd Scientific Meeting of the International Society of Hypertension, 2010 ; Vancouver.

28.

• Alnima T, de Leeuw PW, Tan RES, Kroon AA. Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension. Hypertension. 2013;61:1334–9. Long-term carotid baroreflex activation has no adverse effect on renal function.PubMedCrossRef

29.

Kroon A, Schmidli J, Scheffers I, et al. Chronically implanted system: 4-year data of Rheos DEBuT-HT study in patients with resistant hypertension. J Hypertension. 2010;28(Suppl A):e441.

30.

Wustmann K, Kucera JP. Scheffers I, et al Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54:530–6.PubMedCrossRef

31.

Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6:152–8.PubMedCrossRef

32.

Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619–26.PubMedCrossRef

33.

Bisognano JD, de Leeuw P, Bach DS, et al. Improved cardiac structure and function in early-stage heart failure with chronic treatment using an implantable device: results from European and United States trials of the Rheos® system. J Cardiac Fail. 2008;14 Suppl 1:S48.CrossRef

34.

de Leeuw P, Gangahar D, Bach DS, et al. Left ventricular reverse remodeling with chronic treatment of resistant hypertension using an implantable device: results from European and United States trials of the Rheos® Baroreflex Hypertension Therapy system. J Hypertension. 2008;26 Suppl 1:S471.

35.

Whitelaw GP, Kinsey D, Smithwick RH. Factors influencing the choice of treatment in essential hypertension: surgical, medical, or a combination of both. Am J Surg. 1964;107:220–31.PubMedCrossRef

36.

Allen EV. Sympathectomy for essential hypertension. Circulation. 1952;4:744–59.

37.

Goodfriend TL. Angiotensins: actions and receptors. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension primer. 4th ed. Dallas: American Heart Association; 2008. p. 54–8.

38.

Isberg EM, Peet MM. The influence of supradiaphragmatic splanchnicectomy on the heart in hypertension. Am Heart J. 1948;35:567–83.PubMedCrossRef

39.

Smithwick RH. Surgical treatment of hypertension. Am J Med. 1948;4:744–59.PubMedCrossRef

40.

Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension: review of 122 cases. Lancet. 1953;1:403–8.PubMedCrossRef

41.

Johns EJ. Renal sympathetic nerves and extracellular fluid volume regulation. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension primer. 4th ed. Dallas: American Heart Association; 2008. p. 126–8.

42.

Barajas L, Powers K, Wang P. Innervation of the renal cortical tubules: a quantitative study. Am J Physiol. 1984;247:F50–60.PubMed

43.

Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13:S99–105.CrossRef

44.

Esler M, Rumantir M, Kaye D, et al. Sympathetic nerve biology in essential hypertension. Clin Exp Pharmacol Physiol. 2001;28:986–9.PubMedCrossRef

45.

Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol. 2010;105:570–6.PubMedCrossRef

46.

Burke GM, Sica DA, Frishman WH. Renal sympathetic denervation for the treatment of systemic hypertension. Cardiol Rev. 2012;20:274–8.PubMedCrossRef

47.

Wurzner G, Chiolero A, Maillard M, et al. Renal and neurohormonal responses to increasing levels of lower body negative pressure in men. Kidney Int. 2001;60:1469–76.PubMedCrossRef

48.

DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–97.PubMed

49.

Kopp UC, DiBona GF. The neural control of renal function. In: Seldin G, Giebisch G, editors. The kidney: physiology and pathophysiology. 3rd ed. New York: Raven; 2006. p. 981–1006.

50.

Bello-Reuss E, Conlindres RE, Pastoriza-Munoz E, et al. Effects of acute unilateral renal denervation in the rat. J Clin Invest. 1975;56:208–17.PubMedCentralPubMedCrossRef

51.

Bello-Reuss E, Pastoriza-Munoz E, Colindres RE. Acute unilateral renal denervation in rats with extracellular volume expansion. Am J Physiol. 1977;232:F26–32.PubMed

52.

La Grange RG, Sloop CH, Schmid HE. Selective stimulation of renal nerves in the anaesthetized dog.Effect on renin release during controlled changes in renal hemodynamics. Circ Res. 1973;33:704–12.PubMedCrossRef

53.

Hesse IF, Johns EJ. The effect of graded renal nerve stimulation on renal function in the anaesthetized rabbit. Comp Biochem Physiol A Comp Physiol. 1984;79:409–14.PubMedCrossRef

54.

Johns EJ, Manitius J. An investigation into the neural regulation of calcium excretion by the rat kidney. J Physiol. 1987;383:745–55.PubMedCentralPubMed

55.

DiBona GF, Sawin LL. Effect of renal nerve stimulation on NaCl and H₂O transport in Henle’s loop of the rat. Am J Physiol. 1982;243:F576–80.PubMed

56.

Bonjour JP, Churchill PC, Malvin RL. Change of tubular reabsorption of sodium and water after renal denervation in the dog. J Physiol. 1969;204:571–83.PubMedCentralPubMed

57.

Szenasi G, Bencsath P, Takacs L. Proximal tubular transport and urinary excretion of sodium after renal denervation in sodium depleted rats. Pflugers Arch. 1985;403:146–50.PubMedCrossRef

58.

Wu XC, Johns EJ. Interactions between nitric oxide and superoxide on the neural regulation of proximal fluid reabsorption in hypertensive rats. Exp Physiol. 2004;89:255–61.PubMedCrossRef

59.

Wu XC, Johns EJ. Nitric oxide modulation of neurally induced proximal tubular fluid reabsorption in the rat. Hypertension. 2002;39:790–3.PubMedCrossRef

60.

Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999;79:143–80.PubMed

61.

Wu W, Scholey JW, Sonnenberg H, Melo LG. Renal vascular morphology and haemodynamics in Dahl salt-sensitive rats on high salt low potassium diet: neural and genetic influences. J Hypertens. 2000;18:783–93.PubMedCrossRef

62.

Kopp UC, Cicha MZ, Nakamura K, et al. Activation of EP4 receptors contributes to prostaglandin E2-mediated stimulation of renal sensory nerves. Am J Physiol Renal Physiol. 2004;287:F1269–82.PubMedCrossRef

63.

Kopp UC, Cicha MZ, Smith LA, Hokfelt T. Nitric oxide modulates renal sensory nerve fibers by mechanisms related to substance P receptor activation. Am J Physiol Regul Integr Comp Physiol. 2001;281:R279–90.PubMed

64.

Liu L, Barajas L. The rat renal nerves during development. Anat Embryol (Berl). 1993;188:345–61.CrossRef

65.

Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659–82.PubMed

66.

Caralesu FR, Ciriello J. Renal afferent nerves affect discharge rate of medullary and hypothalamic single units in the cat. J Auton Nern Syst. 1981;3:311–20.CrossRef

67.

Ciriello J. Afferent renal inputs to paraventricular nucleus vasopressin and oxytocin neurosecretory neurons. Am J Physiol. 1998;275:R1745–54.PubMed

68.

Caverson MM, Ciriello J. Effect of stimulation of afferent renal nerves on plasma levels of vasopressin. Am J Physiol. 1987;252:R801–7.PubMed

69.

Coote JH. A role for the paraventricular nucleus of the hypothalamus in the autonomic control of heart and kidney. Exp Physiol. 2004;90:169–73.PubMedCrossRef

70.

Ferguson AV, Latchford KJ, Samson WK. The paraventricular nucleus of the hypothalamus—a potential target for integrative treatment of autonomic dysfunction. Expert Opin Ther Targets. 2008;12:717–27.PubMedCentralPubMedCrossRef

71.

Zhong MK, Duan YC, Chen AD, et al. Paraventricular nucleus is involved in the central pathway of cardiac sympathetic afferent reflex in rats. Exp Physiol. 2008;93:746–53.PubMedCrossRef

72.

Esler M, Jennings G. Korner P, et al Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3–20.PubMedCrossRef

73.

Katholi RE. Renal nerves and hypertension: an update. Fed Proc. 1985;44:2846–50.PubMed

74.

Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878–82.PubMedCrossRef

75.

Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol. 1983;245:F1–14.PubMed

76.

Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol. 1994;4:1901–7.PubMed

77.

Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51:722–7.PubMedCrossRef

78.

Pan JY, Bishop VS, Ball NA, Haywood JR. Inability of dorsal spinal rhizotomy to prevent renal wrap hypertension in rats. Hypertension. 1985;7:722–8.PubMedCrossRef

79.

Zoler ML. Hopes high for device to treat resistant HT. Cardiol News. 2012;10(2):1.

80.

Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.CrossRef

81.

Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:1176–82.PubMedCrossRef

82.

Brandt MC, Mahfoud F. Reda S, et al Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9.PubMedCrossRef

83.

Pokushalov E, Romanov V, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation. J Am Coll Cardiol. 2012;60:1163–70.PubMedCrossRef

84.

Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension. A pilot study. Circulation. 2011;123:1940–6.PubMedCrossRef

85.

Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250–7.PubMedCentralPubMedCrossRef

86.

Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:231–41.PubMedCrossRef

87.

Eleid MF, Schwartz GL, Gulati R. Renal denervation for hypertension. Curr Probl Cardiol. 2014;39:29–52.CrossRef

88.

O’Riordan M. Renal denervation fails in SYMPLICITY HTN-3. http://www.medscape.com/viewarticle/818938. Accessed 9 Jan 2014.

89.

O’Riordan M. SYMPLICITY HTN-3 complicates renal-denervation field, say experts. http://www.medscape.com/viewarticle/819018. Accessed 9 Jan 2014.

90.

Aronow WS. Renal sympathetic denervation therapy for treatment of resistant hypertension. Hypertension. 2014;3:1.

91.

Renal sympathetic denervation for hypertension. Med Lett Drugs Ther 2012; 54:55.

92.

• Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132–40. Multiple catheters are being developed as alternatives to the Symplicity catheter. This trial describes a multielectrode catheter that may be easier to use for abolishing sympathetic innervation of the renal artery.PubMedCentralPubMedCrossRef

93.

• Ahmed H, Neuzil P, Skoda J, et al. Renal sympathetic denervation using an irrigated radio-frequency ablation catheter for the management of drug-resistant hypertension. J Am Coll Cardiol Interv. 2012;5:758–65. This study describes the use of an irrigated radiofrequency ablation catheter for RSD. This catheter is typically used for cardiac tissue ablation.CrossRef

94.

• Wang Q, Gun R, Rong S, et al. Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. J Am Coll Cardiol. 2013;61:2185–92. In this animal study, RSD was obtained by a noninvasive ultrasound technique, which could avoid catheterizations.PubMedCrossRef

95.

Barbash IM, Waksman R. Sympathetic renal denervation: hypertension beyond SYMPLICITY. Cardiovasc Revasc Med. 2013;14:229–35.PubMedCrossRef

96.

Mohaupt MG, Schmidli J, Luft FC. Management of uncontrollable hypertension with a carotid sinus stimulation device. Hypertension. 2007;50:825–8.PubMedCrossRef

97.

Alnima T, Scheffers I, DeLeeuw PW, et al. Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. J Hypertens. 2012;30:1665–70.PubMedCrossRef

Title: The Role of Nonpharmacologic Device Interventions in the Management of Drug-Resistant Hypertension
Authors: William H. Frishman
Daniel Glicklich
Publication date: 01-05-2014
Publisher: Springer US
Published in: Current Atherosclerosis Reports / Issue 5/2014
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-014-0405-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors

The Endothelium in Diabetic Nephropathy

Adiposopathy, “Sick Fat,” Ockham’s Razor, and Resolution of the Obesity Paradox

Noncoding RNAs and Atherosclerosis

Pharmacogenetics of Antiplatelet Therapy

Dissecting the Causal Genetic Mechanisms of Coronary Heart Disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials